-

BlueRidge Life Sciences Acquires Design Science to Expand Human Factors and Usability Engineering Capabilities

KATY, Texas--(BUSINESS WIRE)--BlueRidge Life Sciences (“BlueRidge”), a leading life sciences consulting and services platform and a portfolio company of Renovus Capital Partners, today announced the acquisition of Design Science, a premier human factors and usability engineering consultancy serving medical device, pharmaceutical, and biotechnology companies worldwide.

Founded in 1991, Design Science is recognized for its deep expertise in human factors engineering, usability testing, and use-related risk analysis for complex medical devices and combination products. The company employs a multidisciplinary team of engineers, designers, psychologists, and researchers and operates state-of-the-art usability laboratories across the United States and Europe. Design Science has built long-standing relationships with global life sciences clients and is widely regarded as a trusted partner in navigating FDA and international regulatory requirements.

“This acquisition meaningfully expands BlueRidge’s capabilities across the product lifecycle,” said Ian Kelly, Chief Executive Officer of BlueRidge Life Sciences. “Human factors and usability engineering are increasingly critical to regulatory success, patient safety, and commercial adoption. Design Science brings exceptional talent, a strong culture, and a best-in-class scientific approach that complements our existing offerings and strengthens the value we deliver to clients.”

Design Science will continue to operate under its existing brand while integrating into the BlueRidge platform. Katie Hansbro, Chief Executive Officer of Design Science, will continue to lead the business alongside the current leadership team.

“Joining BlueRidge is an exciting next chapter for Design Science,” said Hansbro. “Our teams share a commitment to scientific rigor, collaboration, and client impact. Together, we will be able to offer more comprehensive solutions to life sciences innovators as products move from development through commercialization.”

The combination enhances BlueRidge’s ability to support clients across clinical development, regulatory strategy, and commercialization by adding differentiated human factors expertise, including formative and validation usability studies, risk analyses, labeling and training development, and ethnographic research. The partnership also creates opportunities for expanded collaboration across BlueRidge’s broader platform to better serve pharmaceutical and medical device sponsors globally.

“This acquisition underscores our belief that differentiated knowledge and exceptional talent are the foundation of enduring services businesses,” said Pat Heath, Principal of Renovus Capital Partners. “Design Science has built a world-class team of scientists, engineers, and designers with deep domain expertise in human factors. By joining BlueRidge, that talent and institutional knowledge become an even more powerful asset—enhancing BlueRidge’s ability to solve complex problems for clients and create meaningful opportunities for the professionals who do this work.”

About BlueRidge Life Sciences

BlueRidge Life Sciences is a specialized life sciences consulting and services platform providing scientific, regulatory, and commercialization support to pharmaceutical, biotechnology, and medical device companies. BlueRidge partners with clients across the product lifecycle to help accelerate development, support regulatory success, and drive long-term value.

About Design Science

Founded in 1991, Design Science is a life sciences consulting firm focused on human factors engineering and usability for medical devices and combination products. With offices in the United States and Europe, Design Science helps clients improve product safety, usability, and regulatory readiness through rigorous research, usability testing, and user-centered design.

About Renovus Capital Partners

Founded in 2010, Renovus Capital Partners is a lower middle-market private equity firm specializing in the Knowledge and Talent industries. From its base in the Philadelphia area, Renovus manages over $2 billion of assets across its several sector focused funds. The firm's current portfolio includes over 30 U.S. based businesses specializing in education and workforce development and services companies in the technology, healthcare, and professional services markets. Renovus typically makes control buyout investments in founder owned businesses, leveraging its industry expertise and operator network to make operational improvements, recruit top talent and pursue add-on acquisitions. Visit us at www.renovuscapital.com and follow us on LinkedIn.

Contacts

Media Contact:
Mark Semer/Alex Jeffrey
Gasthalter & Co.
212-257-4170
Renovus@gasthalter.com

Renovus Capital Partners


Release Versions

Contacts

Media Contact:
Mark Semer/Alex Jeffrey
Gasthalter & Co.
212-257-4170
Renovus@gasthalter.com

More News From Renovus Capital Partners

Renovus Capital Partners Announces Strategic Partnership with Aspire Home Health Care

WAYNE, Pa.--(BUSINESS WIRE)--Renovus Capital Partners (“Renovus”) today announced a strategic partnership with Aspire Home Health Care (“Aspire” or the “Company”), a leading provider of orthopedic and traditional home health services in the Chicagoland area. Aspire provides skilled nursing and therapy services to patients recovering at home from orthopedic procedures, surgeries, and various complex medical conditions. Demand for Aspire’s services is robust and growing, driven by the aging US po...

Definian Appoints Steve Lyerly as Chief Executive Officer

CHICAGO--(BUSINESS WIRE)--Definian, a leader in data and AI solutions and a Renovus Capital Partners portfolio company, today announced the appointment of Steve Lyerly as Chief Executive Officer, effective October 1, 2026. Steve brings more than 20 years of experience building and scaling technology services businesses, developing go-to-market organizations, and cultivating strategic relationships across technology ecosystems. Most recently, he served as Senior Vice President of Cloud Services...

TJP Expands Market Access and Commercial Execution Capabilities Through Addition of FX2 Virtual

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--TJP, an agency specializing in strategic, creative, and digital solutions for patient and market access teams as well as consumer brands, and portfolio company of Renovus Capital Partners, today announced its add-on of FX2 Virtual. FX2 Virtual is a specialized life sciences commercial operations agency led by pharmaceutical industry veterans Ed Kessig, Jeff Cino and Sal Paolozza that provides high-impact virtual sales professionals, patient access reimburseme...
Back to Newsroom